Status:
TERMINATED
MK6186 in HIV-1 Infected Patients (MK-6186-007 AM2)
Lead Sponsor:
Merck Sharp & Dohme LLC
Conditions:
HIV-1 Infection
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
This study will evaluate the safety and tolerability of MK6186 and the change from baseline in plasma HIV-1 RNA after seven consecutive days of dosing.
Eligibility Criteria
Inclusion
- Other than HIV infection, patient's baseline health is judged to be stable
- Patient is documented HIV-1 positive
- Patient has not received an investigational agent or licensed ART with in the past 30 days
Exclusion
- Patient has a history of stroke, chronic seizures, or major neurological disease
- Patient has a history of cancer
- Patient has used any immune therapy agents or immunosuppressive therapy within the past month
- Patient requires or anticipates the use of any prescription or non-prescription drugs during the study
- Patient has a current diagnosis of acute hepatitis, has a history of Hepatitis C or has positive Hepatitis B surface antigen
- Patient consumes excessive amounts of alcohol (greater than 3 servings per day) or caffeine (greater than 6 servings per day)
- Patient is an excessive smoker (more than 10 cigarettes per day)
- Patient has had major surgery, donated blood or participated in another investigational study within the past 4 weeks
Key Trial Info
Start Date :
October 10 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2011
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT01152255
Start Date
October 10 2010
End Date
June 30 2011
Last Update
July 23 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.